Join to View Full Profile
9000 W Wisconsin Ave# PediatriMilwaukee, WI 53226
Phone+1 414-266-3464
Fax+1 414-266-3466
Dr. Harmelink is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Matthew Harmelink is a pediatric specialist with a subspecialty in child neurology, based in Milwaukee, WI. He completed his medical education at the Medical College of Wisconsin, followed by a fellowship in neuromuscular medicine at UCLA David Geffen School of Medicine. Dr. Harmelink’s experience includes child neurology and neuromuscular medicine, with publications in prominent journals such as Molecular Therapy and Lancet. He has been involved in clinical trials concerning spinal muscular atrophy and long-term outcomes of treatment in Duchenne muscular dystrophy. Currently, he is the Therapeutic Head of Neuromusuclar and Senior Medical Director for Solid Biosciences.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Neuromuscular Medicine (Neurology), 2015 - 2016
Medical College of Wisconsin Affiliated HospitalsFellowship, Child Neurology, 2012 - 2015
University of California (Irvine)/Children's Hospital of Orange CountyResidency, Pediatrics, 2009 - 2012- Medical College of WisconsinClass of 2009
Certifications & Licensure
CA State Medical License 2010 - Present
WI State Medical License 2012 - 2027
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Start of enrollment: 2017 Jul 06
- Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) Start of enrollment: 2018 Sep 25
Publications & Presentations
PubMed
- IL-1ra and CCL5, but not IL-10, are promising targets for treating SMA astrocyte-driven pathology.Reilly L Allison, Cecelia C Mangione, Mya Suneja, Jessica Gawrys, Brendan M Melvin
Molecular Therapy. 2025-02-05 - 9 citationsOutcomes of early-treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study.Natalie L Goedeker, Amanda Rogers, Mark Fisher, Kapil Arya, John F Brandsema
Muscle & Nerve. 2024-12-01 - Adolescent Onset of Muscle Weakness.Meghan K Konda, Matthew Harmelink
The Medical Clinics of North America. 2024-01-01
Abstracts/Posters
- De Novo versus None, Two Ends of a SpectrumMatthew Harmelink, Perry Shieh, Carrell-Krusen Conference- UT-Southwestern, 2/29/2016
- Case of Congenital Hypotonia due to a Rare Genetic Deletion: 46,XX (del)14q32.2q32.3Nadir Khan, Kumar Sannagowdara, Matthew Harmelink, AAN Annual Meeting, 4/1/2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
